血紅素疾病市場規模、佔有率和成長分析：按疾病、診斷方法、治療方法、最終用戶、篩檢項目、銷售管道和地區分類－2026-2033年產業預測

2024 年全球血紅素疾病市場價值為 69.5 億美元，預計到 2025 年將成長至 76.7 億美元，到 2033 年將成長至 169.3 億美元，在預測期（2026-2033 年）內複合年成長率為 10.4%。

全球血紅蛋白疾病市場受到遺傳性紅血球疾病（尤其是鐮狀細胞貧血和BETA-地中海貧血）盛行率上升的顯著影響，這推動了對診斷、治療和新生兒篩檢的需求。在基因治療技術進步的推動下，該市場正從傳統治療方法轉向分子診斷和基因編輯技術，從而改善患者預後。分子診斷技術的進步至關重要，它能夠實現早期檢測和精準治療，並減少併發症和發病率。此外，人工智慧（AI）透過簡化資料工作流程和實現複雜基因組及臨床資訊的自動解讀，正在革新診斷和管理方式。這些創新提高了臨床效率，支持個人化護理方案，鼓勵對可擴展的醫療服務項目進行投資，並最終促進市場擴張，從而改善醫療保健效果。

全球血紅素疾病市場的成長要素

基因療法在血紅蛋白疾病治療中的應用日益廣泛，正顯著推動市場成長，並將治療模式轉變為潛在的根治性方案。這一轉變帶動了對專業診斷、治療輸送系統和持續患者管理服務的需求成長。製造商、醫療服務提供者和支付方之間的合作正在加強對研發和准入途徑的支持，從而促進投資、策略夥伴關係和商業化進程。隨著人們對永續治療效果的信心不斷增強，主要相關人員正致力於開發和整合創新解決方案，這不僅拓寬了市場格局，也為整個價值鏈創造了更多機會。

全球血紅素疾病市場的限制因素

全球血紅素疾病市場面臨許多限制因素，這些因素源自於開發先進治療方法所面臨的科學和物流挑戰。這些疾病的複雜性，加上對個人化治療策略和嚴格生產要求的需求，需要專業知識和基礎設施，而這些資源目前並不普及。此外，推動法規核准流程需要充足的證據和協作，而擴大複雜治療方法的生產規模也帶來了額外的營運難題。這些相互作用的因素減緩了新治療方法的推出速度，限制了潛在競爭者的數量，並阻礙了相關人員對市場成長的投資。

全球血紅素疾病市場趨勢

全球血紅蛋白疾病市場正呈現出顯著的趨勢，即採用創新基因編輯技術，這些技術正在重新定義治療策略，並有望帶來根治性方案。標靶化和遞送機制的精準性提升，使得對致病基因的修飾更加有效，從而促進了學術機構、生物技術公司和醫療網路之間的合作。隨著法規環境和臨床框架不斷適應這些進步，人們越來越關注確保長期安全性和最佳化患者選擇。此外，專業化生產和護理流程的開發，正在促進策略夥伴關係，並推動轉化研究的投資，從而進一步加速市場成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球血紅素疾病市場規模：依疾病適應症分類

• 鐮狀細胞貧血症
• 地中海型貧血
  • α地中海貧血
  • BETA-地中海型貧血
• 其他

全球血紅素疾病市場規模：依診斷方法分類

• 血紅素電泳
• 高效液相層析
• 基因檢測
• 定序
• 質譜分析
• 其他

全球血紅素疾病市場規模：依治療類型分類

• 輸血
• 鐵螯合療法
• 藥物治療
• 骨髓移植
• 基因治療
• 基因編輯
• 其他

全球血紅素疾病市場規模：依最終用戶分類

• 診斷檢查室
• 專科醫院
• 學術機構
• 研究機構
• 其他

全球血紅素疾病市場規模：依篩檢項目分類

• 新生兒篩檢
• 產前篩檢
• 學校健康檢查
• 其他

全球血紅素疾病市場規模：依銷售管道分類

• 直接向醫療機構銷售
• 診斷試劑盒批發商
• 其他

全球血紅素疾病市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Pfizer
• Novartis
• Global Blood Therapeutics
• Bluebird Bio
• Vertex Pharmaceuticals
• CRISPR Therapeutics
• Bristol Myers Squibb
• Sangamo Therapeutics
• Editas Medicine
• Agios Pharmaceuticals
• Sangamo Therapeutics
• Apotex
• Terumo BCT
• Emmaus Life Sciences
• Silence Therapeutics
• Modus Therapeutics
• Ironwood Pharmaceuticals
• Cyclerion Therapeutics
• Bioverativ
• Beam Therapeutics

結論與建議

Global Hemoglobinopathies Market size was valued at USD 6.95 Billion in 2024 and is poised to grow from USD 7.67 Billion in 2025 to USD 16.93 Billion by 2033, growing at a CAGR of 10.4% during the forecast period (2026-2033).

The global hemoglobinopathies market is significantly influenced by the rising prevalence of inherited red blood cell disorders, particularly sickle cell disease and beta thalassemia, driving demand for diagnostics, therapies, and newborn screening. The market is transitioning from traditional treatments towards molecular diagnostics and gene-editing technologies, bolstered by advancements in gene therapies that enhance patient outcomes. Technological progress in molecular diagnostics is essential, allowing for earlier identification and precision treatment, which reduces complications and morbidity. Additionally, artificial intelligence is revolutionizing diagnosis and management by streamlining data workflows and enabling automated interpretation of complex genomic and clinical information. These innovations enhance clinical efficiency, support personalized care plans, and stimulate investment in scalable access programs, ultimately reinforcing the market's expansion and improving healthcare outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hemoglobinopathies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hemoglobinopathies Market Segments Analysis

Global hemoglobinopathies market is segmented by disease indication, diagnostic method, therapy type, end-user, screening program, sales channel and region. Based on disease indication, the market is segmented into Sickle Cell Disease, Thalassemia and Others. Based on diagnostic method, the market is segmented into Hemoglobin Electrophoresis, High-Performance Liquid Chromatography, Genetic Testing, Sequencing, Mass Spectrometry and Others. Based on therapy type, the market is segmented into Blood Transfusion, Iron Chelation, Pharmacological Therapy, Bone Marrow Transplant, Gene Therapy, Gene Editing and Others. Based on end-user, the market is segmented into Diagnostic Laboratories, Specialized Hospitals, Academic Institutes, Research Institutes and Others. Based on screening program, the market is segmented into Newborn Screening, Prenatal Screening, School Screening and Others. Based on sales channel, the market is segmented into Direct Institutional Sales, Diagnostic Kit Wholesalers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hemoglobinopathies Market

The increasing adoption of gene therapies for hemoglobinopathies is significantly influencing the growth of the market by transforming care models towards potentially curative options. This shift boosts the need for specialized diagnostics, treatment delivery systems, and ongoing patient management services. Collaborative efforts among manufacturers, healthcare providers, and payers are enhancing support for development and access pathways, leading to heightened investment, strategic partnerships, and commercialization efforts. As confidence in sustainable therapeutic results grows, key stakeholders are focusing on the creation and integration of innovative solutions, which in turn broadens the market landscape and fosters greater opportunities throughout the value chain.

Restraints in the Global Hemoglobinopathies Market

The Global Hemoglobinopathies market faces significant restraints stemming from the scientific and logistical challenges involved in creating advanced therapies. The complex nature of these diseases, along with the need for personalized treatment strategies and stringent manufacturing requirements, demands specialized expertise and infrastructure that are often not widely accessible. Furthermore, navigating regulatory pathways requires substantial evidence and collaboration, while scaling production of intricate therapies presents additional operational difficulties. These intertwined factors slow the introduction of new treatments into the market, limit the number of potential competitors, and dampen the readiness of stakeholders to invest in market growth.

Market Trends of the Global Hemoglobinopathies Market

The global hemoglobinopathies market is witnessing a significant trend toward the adoption of innovative gene editing technologies, which are redefining treatment strategies and steering them toward potentially curative solutions. Enhanced precision in targeting and delivery mechanisms allows for more effective modifications of the genes responsible for these disorders, fostering collaborations among academic institutions, biotechnology companies, and healthcare networks. As regulatory environments and clinical frameworks adapt to these advancements, there is a growing focus on ensuring long-term safety and optimal patient selection. Additionally, the development of specialized manufacturing and care pathways is fueling strategic partnerships and driving investments in translational research, further propelling market growth.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Hemoglobinopathies Market Size by Disease Indication & CAGR (2026-2033)

• Market Overview
• Sickle Cell Disease
• Thalassemia
  • Alpha Thalassemia
  • Beta Thalassemia
• Others

Global Hemoglobinopathies Market Size by Diagnostic Method & CAGR (2026-2033)

• Market Overview
• Hemoglobin Electrophoresis
• High-Performance Liquid Chromatography
• Genetic Testing
• Sequencing
• Mass Spectrometry
• Others

Global Hemoglobinopathies Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Blood Transfusion
• Iron Chelation
• Pharmacological Therapy
• Bone Marrow Transplant
• Gene Therapy
• Gene Editing
• Others

Global Hemoglobinopathies Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Diagnostic Laboratories
• Specialized Hospitals
• Academic Institutes
• Research Institutes
• Others

Global Hemoglobinopathies Market Size by Screening Program & CAGR (2026-2033)

• Market Overview
• Newborn Screening
• Prenatal Screening
• School Screening
• Others

Global Hemoglobinopathies Market Size by Sales Channel & CAGR (2026-2033)

• Market Overview
• Direct Institutional Sales
• Diagnostic Kit Wholesalers
• Others

Global Hemoglobinopathies Market Size & CAGR (2026-2033)

• North America (Disease Indication, Diagnostic Method, Therapy Type, End-User, Screening Program, Sales Channel)
  • US
  • Canada
• Europe (Disease Indication, Diagnostic Method, Therapy Type, End-User, Screening Program, Sales Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Indication, Diagnostic Method, Therapy Type, End-User, Screening Program, Sales Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Indication, Diagnostic Method, Therapy Type, End-User, Screening Program, Sales Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Indication, Diagnostic Method, Therapy Type, End-User, Screening Program, Sales Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Global Blood Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CRISPR Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Editas Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agios Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apotex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Terumo BCT
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Emmaus Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Silence Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Modus Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ironwood Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cyclerion Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioverativ
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beam Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations